Screener
Celldex Therapeutics CLDX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's total liabilities?
- Celldex Therapeutics (CLDX) reported total liabilities of $67.79M in Q2 2026.
- How has Celldex Therapeutics's total liabilities changed year-over-year?
- Celldex Therapeutics's total liabilities increased by 83.2% year-over-year, from $37M to $67.79M.
- What is the long-term trend for Celldex Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Celldex Therapeutics's total liabilities has grown at a 16.1% compound annual growth rate (CAGR), from $26.48M to $55.82M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Celldex Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude